Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / Fund iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer Blackrock
Entity holding fund iShares VII Public Limited Company
Entity Type Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF Ticker CUS1(GBX) LSE
ETF Ticker CUSS(USD) LSE
ETF Ticker SXRG(EUR) F
ETF Ticker CSUSS.MI(EUR) CXE
ETF Ticker CSUSSz(USD) CXE
ETF Ticker CUSS.LS(USD) CXE
ETF Ticker CSUSS(EUR) ETF Plus
ETF Ticker CUS1.L(GBP) LSE
ETF Ticker CUSS.L(GBP) LSE

Holdings detail for ELVN

Stock Name	Enliven Therapeutics Inc.
Ticker	ELVN(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US29337E1029

Show aggregate ELVN holdings

News associated with ELVN

Brokerages Set Enliven Therapeutics, Inc. (NASDAQ:ELVN) PT at $41.20: Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) has earned a consensus recommendation of “Buy” from the five ratings firms that are currently covering the stock, MarketBeat reports. Five analysts have rated the stock with a buy rating. The average 1-year price target among brokers that have updated their coverage on the stock in the […] - 2025-08-08 02:42:46
Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Sells $281,500.00 in Stock: Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) CEO Samuel Kintz sold 12,500 shares of the company’s stock in a transaction dated Thursday, July 17th. The stock was sold at an average price of $22.52, for a total transaction of $281,500.00. Following the transaction, the chief executive officer owned 940,392 shares in the company, valued […] - 2025-07-22 07:14:55
Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl Sells 1,000 Shares: Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) CFO Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock in a transaction dated Thursday, July 10th. The shares were sold at an average price of $22.66, for a total transaction of $22,660.00. Following the transaction, the chief financial officer directly owned 23,000 shares of the company’s […] - 2025-07-15 06:21:06
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Average Recommendation of “Buy” from Brokerages: Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) have received an average recommendation of “Buy” from the five ratings firms that are currently covering the company, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have issued a […] - 2025-07-11 05:23:02
Enliven Therapeutics (NASDAQ:ELVN) Trading 7.9% Higher Following Analyst Upgrade: Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report)’s stock price was up 7.9% on Wednesday after HC Wainwright raised their price target on the stock from $40.00 to $48.00. HC Wainwright currently has a buy rating on the stock. Enliven Therapeutics traded as high as $20.74 and last traded at $21.20. Approximately 171,529 shares traded […] - 2025-07-04 02:24:46
Exchange Traded Concepts LLC Reduces Stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN): Exchange Traded Concepts LLC decreased its holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 19.1% in the 1st quarter, Holdings Channel.com reports. The firm owned 6,055 shares of the company’s stock after selling 1,428 shares during the period. Exchange Traded Concepts LLC’s holdings in Enliven Therapeutics were worth $119,000 as of its most […] - 2025-06-24 04:38:52
Rhumbline Advisers Increases Stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN): Rhumbline Advisers raised its position in Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 4.9% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 52,502 shares of the company’s stock after acquiring an additional 2,466 shares during the period. Rhumbline Advisers’ holdings in Enliven Therapeutics were worth $1,033,000 […] - 2025-06-20 04:22:47
Robert W. Baird Forecasts Strong Price Appreciation for Enliven Therapeutics (NASDAQ:ELVN) Stock: Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) had its target price lifted by equities research analysts at Robert W. Baird from $40.00 to $52.00 in a report issued on Monday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Robert W. Baird’s price target indicates a potential upside of 138.53% from the stock’s […] - 2025-06-18 03:08:46
Enliven Therapeutics (NASDAQ:ELVN) Coverage Initiated at The Goldman Sachs Group: Investment analysts at The Goldman Sachs Group assumed coverage on shares of Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) in a report released on Monday, MarketBeat Ratings reports. The firm set a “buy” rating and a $37.00 price target on the stock. The Goldman Sachs Group’s target price suggests a potential upside of 69.72% from […] - 2025-06-18 03:08:45
Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Up Following Analyst Upgrade: Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report)’s stock price gapped up prior to trading on Monday after Robert W. Baird raised their price target on the stock from $40.00 to $52.00. The stock had previously closed at $21.91, but opened at $23.38. Robert W. Baird currently has an outperform rating on the stock. Enliven […] - 2025-06-17 02:08:49
Two Sigma Investments LP Decreases Stock Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN): Two Sigma Investments LP lowered its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 33.8% during the 4th quarter, HoldingsChannel.com reports. The fund owned 14,620 shares of the company’s stock after selling 7,460 shares during the quarter. Two Sigma Investments LP’s holdings in Enliven Therapeutics were worth $329,000 as of its […] - 2025-06-11 04:30:51
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Acquired by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.: MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 3.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,036 shares of the company’s stock after purchasing an additional 718 shares during the […] - 2025-05-30 04:55:02
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Average Recommendation of “Buy” by Brokerages: Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) have been assigned an average rating of “Buy” from the five analysts that are covering the company, MarketBeat reports. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month […] - 2025-05-27 05:26:58
Voya Investment Management LLC Decreases Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN): Voya Investment Management LLC trimmed its position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 8.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 10,702 shares of the company’s stock after selling 945 shares during the quarter. Voya […] - 2025-05-13 05:22:51
Marshall Wace LLP Has $931,000 Stock Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN): Marshall Wace LLP cut its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 70.0% in the 4th quarter, Holdings Channel reports. The institutional investor owned 41,382 shares of the company’s stock after selling 96,624 shares during the quarter. Marshall Wace LLP’s holdings in Enliven Therapeutics were worth $931,000 at the end […] - 2025-05-01 04:50:53
ExodusPoint Capital Management LP Acquires New Shares in Enliven Therapeutics, Inc. (NASDAQ:ELVN): ExodusPoint Capital Management LP bought a new position in Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 8,900 shares of the company’s stock, valued at approximately $200,000. Other hedge funds have also added to or reduced […] - 2025-04-15 04:39:25
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Bought by Fmr LLC: Fmr LLC grew its stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 3.2% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,495,871 shares of the company’s stock after acquiring an additional 199,692 shares during the quarter. Fmr LLC owned about 0.13% […] - 2025-04-14 05:48:47
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock Holdings Lowered by Corebridge Financial Inc.: Corebridge Financial Inc. cut its stake in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Free Report) by 7.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,500 shares of the company’s stock after selling 1,321 shares during the quarter. […] - 2025-04-10 04:49:04
Enliven Therapeutics (NASDAQ:ELVN) Shares Down 4.9% Following Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report)’s share price traded down 4.9% during mid-day trading on Tuesday following insider selling activity. The stock traded as low as $18.61 and last traded at $18.73. 40,658 shares were traded during mid-day trading, a decline of 85% from the average session volume of 275,231 shares. The stock […] - 2025-04-03 02:44:44
Tuesday's ETF Movers: BLOK, IHE: In trading on Tuesday, the Amplify Transformational Data Sharing ETF is outperforming other ETFs, up about 1.8% on the day. Components of that ETF showing particular strength include shares of Core Scientific, up about 8.1% and shares of Applied Digital, up about 6.6% on the da - 2025-04-01 13:04:57
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Expected to Rise, HC Wainwright Analyst Says: Enliven Therapeutics (NASDAQ:ELVN – Free Report) had its price objective lifted by HC Wainwright from $37.00 to $39.00 in a research report sent to investors on Friday,Benzinga reports. HC Wainwright currently has a buy rating on the stock. Separately, BTIG Research began coverage on Enliven Therapeutics in a report on Friday, December 13th. They set […] - 2025-03-24 04:13:03

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc ELVN holdings

Date	Number of ELVN Shares Held	Base Market Value of ELVN Shares	Local Market Value of ELVN Shares	Change in ELVN Shares Held	Change in ELVN Base Value	Current Price per ELVN Share Held	Previous Price per ELVN Share Held
2025-09-26 (Friday)	56,164	USD 1,123,842	USD 1,123,842
2025-09-25 (Thursday)	56,164	USD 1,042,965	USD 1,042,965	0	USD -35,384	USD 18.57	USD 19.2
2025-09-24 (Wednesday)	56,164	USD 1,078,349	USD 1,078,349
2025-09-17 (Wednesday)	55,800	USD 1,061,316	USD 1,061,316	0	USD 32,922	USD 19.02	USD 18.43
2025-09-16 (Tuesday)	55,800	USD 1,028,394	USD 1,028,394
2025-09-12 (Friday)	55,436	USD 1,106,503	USD 1,106,503
2025-09-11 (Thursday)	55,436	USD 1,104,285	USD 1,104,285

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of ELVN by Blackrock for IE00B3VWM098

Show aggregate share trades of ELVN

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-08-21 SELL -163 19.840* 21.37 Profit of 3,483 on sale
2025-07-31 BUY 489 18.810* 21.39
2025-06-30 SELL -326 20.060* 21.42 Profit of 6,984 on sale
2025-06-25 SELL -163 21.500* 21.43 Profit of 3,493 on sale
2025-06-20 SELL -326 21.300* 21.44 Profit of 6,989 on sale
2025-05-30 BUY 5,672 17.770* 21.50
2025-05-23 BUY 144 16.400* 21.70
2025-05-19 SELL -144 16.850* 21.87 Profit of 3,149 on sale
2025-05-15 SELL -432 17.820* 21.95 Profit of 9,481 on sale
2025-05-12 SELL -144 19.010* 22.01 Profit of 3,169 on sale
2025-05-09 SELL -144 18.420* 22.04 Profit of 3,174 on sale
2025-04-30 SELL -144 18.940* 22.22 Profit of 3,199 on sale
2025-04-24 SELL -288 18.300* 22.37 Profit of 6,441 on sale
2025-04-17 SELL -144 16.530* 22.65 Profit of 3,262 on sale
2025-04-15 SELL -432 17.050* 22.78 Profit of 9,843 on sale
2025-04-14 SELL -432 17.190* 22.85 Profit of 9,869 on sale
2025-04-09 SELL -576 16.520* 23.08 Profit of 13,294 on sale
2025-04-07 SELL -1,008 17.870* 23.22 Profit of 23,410 on sale
2025-04-04 SELL -1,450 18.690* 23.28 Profit of 33,752 on sale
2025-03-31 BUY 145 19.680* 23.42
2025-03-19 SELL -290 20.890* 23.65 Profit of 6,859 on sale
2025-03-14 SELL -870 20.740* 23.78 Profit of 20,687 on sale
2025-03-13 SELL -290 20.290* 23.83 Profit of 6,910 on sale
2025-03-12 SELL -4,930 21.020* 23.87 Profit of 117,674 on sale
2025-03-07 SELL -290 21.000* 24.02 Profit of 6,964 on sale
2025-03-06 SELL -435 21.460* 24.05 Profit of 10,464 on sale
2025-03-03 SELL -145 19.620* 24.24 Profit of 3,514 on sale
2025-02-28 SELL -870 20.830* 24.29 Profit of 21,136 on sale
2025-02-26 SELL -145 20.280* 24.43 Profit of 3,543 on sale
2025-02-25 SELL -435 20.130* 24.51 Profit of 10,660 on sale
2025-02-18 BUY 725 21.820* 24.77
2025-02-13 BUY 145 21.500* 24.96
2025-02-12 BUY 145 22.050* 25.02
2025-02-11 BUY 435 21.410* 25.10
2025-02-06 BUY 1,305 22.470* 25.30
2025-01-27 BUY 145 21.290* 26.10
2024-12-30 BUY 725 22.390* 26.53
2024-12-06 BUY 580 25.420* 26.73
2024-12-05 BUY 145 23.250* 26.85
2024-12-04 BUY 725 23.710* 26.96
2024-11-29 BUY 725 24.380* 27.30
2024-11-27 BUY 580 25.410* 27.46
2024-11-26 BUY 145 24.350* 27.61
2024-11-25 BUY 4,493 24.880* 27.74
2024-11-21 BUY 650 25.410* 28.03
2024-11-20 BUY 390 25.430* 28.17
2024-11-18 BUY 1,560 24.900* 28.50
2024-11-12 BUY 1,040 27.170* 28.59
2024-11-08 BUY 650 28.960* 28.56
2024-11-07 BUY 1,950 29.000* 28.53
2024-11-06 BUY 260 29.550* 28.44
2024-10-31 BUY 130 27.850* 28.77
Market high and low price is on the date.

Date	Action	Quantity	Likely Trade Price	Average Price previous trades
2025-08-21	SELL	-163	19.840*	21.37 Profit of 3,483 on sale
2025-07-31	BUY	489	18.810*	21.39
2025-06-30	SELL	-326	20.060*	21.42 Profit of 6,984 on sale
2025-06-25	SELL	-163	21.500*	21.43 Profit of 3,493 on sale
2025-06-20	SELL	-326	21.300*	21.44 Profit of 6,989 on sale
2025-05-30	BUY	5,672	17.770*	21.50
2025-05-23	BUY	144	16.400*	21.70
2025-05-19	SELL	-144	16.850*	21.87 Profit of 3,149 on sale
2025-05-15	SELL	-432	17.820*	21.95 Profit of 9,481 on sale
2025-05-12	SELL	-144	19.010*	22.01 Profit of 3,169 on sale
2025-05-09	SELL	-144	18.420*	22.04 Profit of 3,174 on sale
2025-04-30	SELL	-144	18.940*	22.22 Profit of 3,199 on sale
2025-04-24	SELL	-288	18.300*	22.37 Profit of 6,441 on sale
2025-04-17	SELL	-144	16.530*	22.65 Profit of 3,262 on sale
2025-04-15	SELL	-432	17.050*	22.78 Profit of 9,843 on sale
2025-04-14	SELL	-432	17.190*	22.85 Profit of 9,869 on sale
2025-04-09	SELL	-576	16.520*	23.08 Profit of 13,294 on sale
2025-04-07	SELL	-1,008	17.870*	23.22 Profit of 23,410 on sale
2025-04-04	SELL	-1,450	18.690*	23.28 Profit of 33,752 on sale
2025-03-31	BUY	145	19.680*	23.42
2025-03-19	SELL	-290	20.890*	23.65 Profit of 6,859 on sale
2025-03-14	SELL	-870	20.740*	23.78 Profit of 20,687 on sale
2025-03-13	SELL	-290	20.290*	23.83 Profit of 6,910 on sale
2025-03-12	SELL	-4,930	21.020*	23.87 Profit of 117,674 on sale
2025-03-07	SELL	-290	21.000*	24.02 Profit of 6,964 on sale
2025-03-06	SELL	-435	21.460*	24.05 Profit of 10,464 on sale
2025-03-03	SELL	-145	19.620*	24.24 Profit of 3,514 on sale
2025-02-28	SELL	-870	20.830*	24.29 Profit of 21,136 on sale
2025-02-26	SELL	-145	20.280*	24.43 Profit of 3,543 on sale
2025-02-25	SELL	-435	20.130*	24.51 Profit of 10,660 on sale
2025-02-18	BUY	725	21.820*	24.77
2025-02-13	BUY	145	21.500*	24.96
2025-02-12	BUY	145	22.050*	25.02
2025-02-11	BUY	435	21.410*	25.10
2025-02-06	BUY	1,305	22.470*	25.30
2025-01-27	BUY	145	21.290*	26.10
2024-12-30	BUY	725	22.390*	26.53
2024-12-06	BUY	580	25.420*	26.73
2024-12-05	BUY	145	23.250*	26.85
2024-12-04	BUY	725	23.710*	26.96
2024-11-29	BUY	725	24.380*	27.30
2024-11-27	BUY	580	25.410*	27.46
2024-11-26	BUY	145	24.350*	27.61
2024-11-25	BUY	4,493	24.880*	27.74
2024-11-21	BUY	650	25.410*	28.03
2024-11-20	BUY	390	25.430*	28.17
2024-11-18	BUY	1,560	24.900*	28.50
2024-11-12	BUY	1,040	27.170*	28.59
2024-11-08	BUY	650	28.960*	28.56
2024-11-07	BUY	1,950	29.000*	28.53
2024-11-06	BUY	260	29.550*	28.44
2024-10-31	BUY	130	27.850*	28.77

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of ELVN

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	255,512	2,440	367,300	69.6%
2025-09-18	205,742	0	372,476	55.2%
2025-09-17	162,926	1,997	258,660	63.0%
2025-09-16	210,614	0	354,409	59.4%
2025-09-15	158,968	15	285,258	55.7%
2025-09-12	150,977	0	331,828	45.5%
2025-09-11	96,060	0	385,686	24.9%
2025-09-10	47,949	6	151,232	31.7%
2025-09-09	131,883	0	239,214	55.1%
2025-09-08	196,306	8,811	347,785	56.4%
2025-09-05	63,256	0	131,309	48.2%
2025-09-04	78,435	0	146,468	53.6%
2025-09-03	105,005	0	189,634	55.4%
2025-09-02	92,210	308	154,107	59.8%
2025-08-29	152,705	246	324,867	47.0%
2025-08-28	113,372	0	320,884	35.3%
2025-08-27	114,853	2,880	257,350	44.6%
2025-08-26	36,937	0	145,789	25.3%
2025-08-25	150,668	0	277,238	54.3%
2025-08-22	164,536	0	493,351	33.4%
2025-08-21	208,223	1,982	440,282	47.3%
2025-08-20	69,564	1,006	132,987	52.3%
2025-08-19	42,058	3,410	78,032	53.9%
2025-08-18	52,776	3,411	113,030	46.7%
2025-08-15	49,843	607	137,044	36.4%
2025-08-14	60,767	0	121,823	49.9%
2025-08-13	77,834	0	145,516	53.5%
2025-08-12	76,411	0	165,024	46.3%
2025-08-11	49,374	0	80,191	61.6%
2025-08-08	148,399	100	336,540	44.1%
2025-08-07	75,044	2,200	122,751	61.1%
2025-08-06	123,117	20	222,055	55.4%
2025-08-05	103,501	0	245,375	42.2%
2025-08-04	36,934	0	99,774	37.0%
2025-08-01	100,865	0	290,379	34.7%
2025-07-31	72,665	0	189,293	38.4%
2025-07-30	83,029	0	128,492	64.6%
2025-07-29	41,527	0	133,286	31.2%
2025-07-28	44,820	1,104	199,290	22.5%
2025-07-25	38,438	6	75,237	51.1%
2025-07-24	72,747	28	125,300	58.1%
2025-07-23	27,864	0	77,643	35.9%
2025-07-22	50,068	0	117,137	42.7%
2025-07-21	63,682	7,051	239,269	26.6%
2025-07-18	39,727	258	109,464	36.3%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer	Blackrock
Entity holding fund	iShares VII Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300Q7FFITMZ2PFZ28
ETF Ticker	CUS1(GBX) LSE
ETF Ticker	CUSS(USD) LSE
ETF Ticker	SXRG(EUR) F
ETF Ticker	CSUSS.MI(EUR) CXE
ETF Ticker	CSUSSz(USD) CXE
ETF Ticker	CUSS.LS(USD) CXE
ETF Ticker	CSUSS(EUR) ETF Plus
ETF Ticker	CUS1.L(GBP) LSE
ETF Ticker	CUSS.L(GBP) LSE